Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Coherus Oncology Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Coherus Oncology Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 06 Dec 2022 | Lorem |
| CMS’ Medicare Advantage step edits in Part B likely to have muted impact on biosimilar uptake due to influence of similar challenges with commercial plans, experts say | 16 Aug 2018 | Manasi Vaidya |
| Coherus BioScience’s Udenyca and CHS-1420 biosimilars for Amgen’s Neulasta and AbbVie’s Humira have market uptake concerns despite likely approvals, experts say | 14 Aug 2018 | Arafa Salam |
| J&J's motion to dismiss Pfizer’s biosimilar antitrust suit might shake up viability of exclusionary contracts if unsuccessful; granted motion could stifle innovation, experts say | 27 Mar 2018 | Shuan Sim,;Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer